According to a report published in Nature Medicine on July 11, 2024, immunotherapy shows some potential effects for certain patients with metastatic solid tumors. Researchers from the National Institutes of Health (NIH) ran a trial with some metastatic colorectal cancer patients. These patients have previously tried various treatment options. The researchers used the lymphocytes of the affected cancer patients. They genetically engineered these to make some receptors in the body. These receptors are produced in such a way that they can identify the specific cancer cells in the body and attack them. The researchers found that with this mechanism, in some patients, the tumors shrank and didn’t regrow until the next seven months. This new technique can increase the number of T cells (which can recognize specific cancer cells) and boost the ability of T cells. According to Steven A. Rosenberg, M.D., Ph.D., of NCI’s Center for Cancer Research (CCR), who co-led the research, chimeric antigen receptor (CAR), T-cell therapy proves efficacy against some blood cancers, and tumor-infiltrating lymphocyte (TIL) therapy against metastatic melanoma. The invention of new cellular immunotherapy shows potential effects on some metastatic solid tumors, which is a new hope for many cancer patients.

Trials are ongoing on many types of solid. We hope that we will be able to find a new technique of immunotherapy to treat cancer.